An interventional study of Seattle-PAP and Conventional bubble nasal CPAP in Premature Birth, sponsored by Seattle Children's Hospital. Status unknown at 1 site in United States. Open to participants aged Up to 30 Weeks. Per ClinicalTrials.gov, last updated 2017-03-22.
Sponsored by Seattle Children's Hospital · Not applicable, Interventional, and Treatment
This study is designed to test the hypothesis that among infants born at less than 30 weeks, weighing less than 1500 g at delivery, and receiving initial respiratory support non-invasively or on invasive respiratory support and meeting extubation criteria in the first 72 h of life, fewer neonates managed on Seattle--PAP will require endotracheal intubation and conventional mechanical ventilation (CMV) than will neonates managed from birth on bubble nasal continuous positive airway pressure (Bn-CPAP) using the Fischer- \& Paykel (FP) device. Neonates on nasal continuous positive airway pressure (CPAP) in the delivery room or who are stabilized on mechanical ventilation as their initial form of respiratory support and meet our criteria for extubation within 72 h of birth will be eligible for randomization and study.
The primary endpoint of this study is the cumulative incidence of respiratory failure requiring intubation that occurs in patients after randomization and before 36 weeks post menstrual age (PMA) or discharge, whichever comes first. Presently, the literature supports that this age group typically exhibits intubation rates of 50% or more, which is consistent with the data from the Nationwide Children's Hospital/Ohio State University (NCH/OSU) Neonatal Intensive Care Unit (NICU).
Parents / Mothers with impending pre-term delivery at \<30 weeks of gestation will be approached for informed consent to participate. If consent is given prior to delivery, upon delivery the neonate may be randomly assigned to either Fisher \& Paykel CPAP (conventional approach) or Seattle--PAP (experimental approach).
First 72 hours of life: 1) Neonates able to breathe spontaneously on less than 40% oxygen after initial resuscitative efforts and would normally be placed on CPAP will be randomly assigned to one of the two treatment groups using sealed cards generated by a variable block randomization scheme. 2) Neonates requiring increased support after initial resuscitation (intubation, >40% oxygen by CPAP) will not initially be randomized. However, if within the first 72 hours of life, the infant meets NCH criteria for extubation, randomization to CPAP delivery method will be performed. 3) Neonates born at \<30 weeks gestation who were intubated at birth and are unable to be weaned from ventilator support will be removed from the study.
72 Hours - 32 Weeks of Life: 1) Neonates from the first period (First 72 Hours of Life, above) who remain on CPAP will continue on randomly assigned CPAP methodology. 2) Neonates from the first period, who failed stabilization on CPAP and required intubation, but are able to be extubated to CPAP will be placed back on their assigned CPAP method. 3) Attempts will be made to wean back to assigned CPAP method any neonates who are >72 hours old and require intubation beyond this period for any reason. 4) If unable to wean back to CPAP prior to 32 weeks of age, these patients will be removed from the study.
CPAP Failure (Sub-Group 1): For the neonates initially assigned to CPAP in the delivery room (sub-group 1), respiratory failure secondary to hyaline membrane disease is recognized as a common occurrence. If a patient assigned to this group, regardless of CPAP methodology, requires a fraction of inspired oxygen (FiO2) greater than 0.40 on CPAP of 6 cm of water (H2O), or is deemed to require intubation for adequate oxygenation, this will be considered a failure of CPAP stabilization. These patients, however, may remain in the study if it becomes clinically feasible to return them back to their assigned CPAP method prior to 72 hours of life. If this is unable to be done, they will be removed from the study.
CPAP Failure (Sub-Group 2): Any neonate that requires FiO2 greater than 0.40 on CPAP of 6 cm H2O or intubation beyond the first 72 hours of life will also be considered CPAP failures. Like those assigned to sub-group 1, these patients may remain in the study if it becomes clinically feasible to return them back to their assigned CPAP method prior to 32 weeks of life. If this is unable to be done, they will be removed from the study.
All patients who are not removed from the study as outlined above or due to other unforeseen circumstances will be monitored to discharge for any change in ventilation and ventilation requirement status. Routine care, including clinical exams and procedures (echocardiography, ultrasound, eye exams, x--rays) that would be considered standard of care for these patients will be performed at the medical discretion of the assigned care providers. No changes other than the type of CPAP device used (if applicable) will be necessary to routine practice.
Transfers to NCH: [From Outside Hospital] - Neonates born at an outside institution who meet the inclusion criteria (\<30 weeks GA, able to spontaneously breathe by 72 hours of life or were initially placed on CPAP and failed, \<32 weeks of age) and whose parents can be reached to obtain consent will be considered for inclusion in this research study. [Transfers from Ohio State University (OSU) Hospital] - It is recognized that many neonates born at OSU will require transport to NCH for further medical care. Having fulfilled inclusion criteria at OSU, transport to NCH will not result in removal from the study.
Cardiopulmonary Monitoring: All neonates are monitored in the NICU using pulse oximetry as part of normal practice. Many potential subjects in this study are also monitored through blood tests and arterial catheters, the latter of which are normally not intended for long term use.
Pressure Monitoring: A stand-alone Data Acquisition and Recording Instrument (DARCI) that measures pressure (i.e., positive airway pressure [PAW]) will be attached to the ventilation circuit. The DARCI unit is equipped with a standard International Organization for Standardization (ISO)19054 pole mount fitting attached on the back. A medical grade plug-in transformer provides electrical power (120 volts alternating current (AC) to 5 volts direct current (DC)). An internal battery and on-board non-volatile memory provide continuous data processing and storage in the event of power interruption or loss. A start button with a green light emitting diode (LED) and a stop button with a red LED provide the operational interface to the user during setup and changes in ventilation circuits. Initial programming and downloading of recorded pressure data will be accomplished using a laptop personal computer (PC) with interface application software installed.
2,554 studies on the registry are indexed under Premature Birth; 498 are open to participants now.
This study's planned enrollment of 220 is above the median of 84 across 1,689 interventional studies indexed under Premature Birth.
Browse Premature Birth studies →Seattle Children's Hospital is the lead sponsor of 210 studies on the registry; 43 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
bubble nasal cpap respiratory support with Seattle-PAP bubbler device, with all other aspects of care per usual care noninvasive respiratory support
Device: Seattle-PAP
qualified and enrolled infants randomized to this arm will receive noninvasive respiratory support by bubble nasal CPAP, using the Fisher \& Paykel bubbler, which is the standard of care at Nationwide Children's.
Device: Conventional bubble nasal CPAP
Seattle-PAP is a modified bubble CPAP device that has been given 510(k) clearance by the US FDA (K131502, October 11, 2013) and is thus recognized as substantially equivalent to other approved devices on the market. Results of a recently completed study in infants indicate that Bn-CPAP is associated with lower effort to breathe by spontaneously breathing premature infants.
Infants enrolled in the study and randomized to this arm will be given respiratory support by bubble nasal CPAP using the Fisher \& Paykel bubbler device, which is the standard of care at Nationwide Children's.
Failure of noninvasive respiratory support
The primary endpoint of this study is the cumulative incidence of respiratory failure requiring intubation. The principal criteria for failure of support are the requirement of an FiO2 greater than 0.40 and CPAP of greater than 6 cm H2O to maintain SaO2 of at least 90%. Support failure also can be declared by the responsible clinician based on best clinical judgment, but any declarations not based on the stated criteria will require written explanations.
Time frame: After randomization and before 36 weeks postmenstrual age (PMA) or discharge from the hospital, whichever comes first.
pneumothorax
by diagnosis of clinical care team
Time frame: After randomization and before 36 weeks postmenstrual age (PMA) or discharge from the hospital, whichever comes first.
nasal trauma
by diagnosis of clinical care team
Time frame: After randomization and before 36 weeks postmenstrual age (PMA) or discharge from the hospital, whichever comes first.
supplemental oxygen requirement
if an infant fails for one hour or more fails to sustain an oxygen saturation (SaO2) of at least 90 percent, with FiO2 of 0.40 or less and 6 cm of water pressure (cmH2O) or less CPAP pressure.
Time frame: After randomization and before 36 weeks postmenstrual age (PMA) or discharge from the hospital, whichever comes first.
ventilation-associated sepsis
by diagnosis of clinical care team
Time frame: After randomization and before 36 weeks postmenstrual age (PMA) or discharge from the hospital, whichever comes first.
death of infant
infant declared dead by responsible clinical care personnel
Time frame: After randomization and before 36 weeks postmenstrual age (PMA) or discharge from the hospital, whichever comes first.
Central nervous system (CNS) injury
intraventricular hemorrhage and/or periventricular leukomalacia
Time frame: After randomization and before 36 weeks postmenstrual age (PMA) or discharge from the hospital, whichever comes first.
gastrointestinal complications
necrotizing enterocolitis and/or spontaneous intestinal perforation
Time frame: After randomization and before 36 weeks postmenstrual age (PMA) or discharge from the hospital, whichever comes first.
retinopathy of prematurity
by diagnosis of clinical care team
Time frame: After randomization and before 36 weeks postmenstrual age (PMA) or discharge from the hospital, whichever comes first.
Plan to share: Yes — The data will be available for download via Globus sharing services from the Seattle-PAP shared endpoint.
This study is status unknown, as verified in Mar 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Seattle Children's Hospital